Boston starts spine stimulation study
This article was originally published in Clinica
Executive Summary
Boston Scientific has kicked off a study of its Precision Plus spinal cord stimulator system. The randomised, controlled EVIDENCE trial will enrol 132 patients who had previously undergone spinal surgery which had failed to alleviate persistent back and leg pain. The study will compare the therapeutic efficacy and cost-effectiveness of spinal cord stimulation (SCS) therapy using the Precision Plus system with spine reoperation. The rates of leg pain relief with no request for the alternative therapy with both strategies will be compared at six and 24 months. The Precision Plus delivers electrical signals via the spinal cord to the brain. These pulses change pain signals into signals that the brain interprets as a pleasant sensation. It is indicated for aiding the management of chronic pain in the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery and intractable lower back and leg pain.
You may also be interested in...
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
Roche Steals A March In B-cell Lymphoma
New data on Columvi could allow the bispecific’s use as an earlier treatment, giving it a three-year head start on AbbVie and Genmab’s Epkinly.